The Covishield vaccine effectiveness against SARS-CoV-2 infection in fully vaccinated individuals was found to be 63 percent during the second wave, according to a study.
The vaccine effectiveness of complete vaccination against moderate-to-severe disease was even much higher at 81 percent, says the result of the study published in journal "The Lancet Infectious Diseases".
To estimate the effectiveness of two doses of the vaccine, 2,379 confirmed cases and 1,981 healthy individuals were analysed.
A multi-institutional team of Indian researchers led by Translational Health Science and Technology Institute (THSTI) evaluated the real-world vaccine effectiveness of Covishield during the SARS-CoV-2 infection surge between April and May 2021 in India.
They also assessed neutralising activity and cellular immune responses against the variants in healthy vaccinated people to understand the mechanisms of protection.
The scientists also observed that the Spike-specific T-cell responses were conserved against both the delta variant and wild-type SARS-CoV-2. Such cellular immune protection might compensate for waning humoral immunity against the virus variants and prevent moderate-to-severe disease and need for hospitalisation, underlined the study.
The study provides comprehensive data on the real-world vaccine effectiveness and immunological response to vaccination which should help guide policy.
The study thus implies that the vaccines continued to be effective in protecting against severe disease and death regardless of the variants.
Meanwhile, India has started projecting declining trends in the daily COVID caseload. India reported 6,990 fresh COVID cases in the past 24 hours, below the 10,000-mark for a fourth consecutive day. The active caseload stands at 1,00,543, the lowest in the last 546 days.
(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)